biguanides has been researched along with Glioma in 4 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 7.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 3.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbieri, F | 1 |
| Bosio, AG | 1 |
| Pattarozzi, A | 1 |
| Tonelli, M | 1 |
| Bajetto, A | 1 |
| Verduci, I | 1 |
| Cianci, F | 1 |
| Cannavale, G | 1 |
| Palloni, LMG | 1 |
| Francesconi, V | 1 |
| Thellung, S | 1 |
| Fiaschi, P | 1 |
| Mazzetti, S | 1 |
| Schenone, S | 1 |
| Balboni, B | 1 |
| Girotto, S | 1 |
| Malatesta, P | 1 |
| Daga, A | 1 |
| Zona, G | 1 |
| Mazzanti, M | 1 |
| Florio, T | 1 |
| Barnes, JM | 1 |
| Barnes, NM | 1 |
| Rondé, P | 1 |
| Nichols, RA | 1 |
| Boess, FG | 1 |
| Sepúlveda, MI | 1 |
| Lummis, SC | 1 |
| Martin, IL | 1 |
4 other studies available for biguanides and Glioma
| Article | Year |
|---|---|
Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives.
Topics: Biguanides; Cell Line, Tumor; Chloride Channels; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2022 |
Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Topics: Animals; Benzamides; Biguanides; Binding Sites; Binding, Competitive; Bridged Bicyclo Compounds; Bri | 1993 |
High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum.
Topics: Animals; Biguanides; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Membrane Permeability | 1998 |
5-HT3 receptors in NG108-15 neuroblastoma x glioma cells: effect of the novel agonist 1-(m-chlorophenyl)-biguanide.
Topics: Animals; Biguanides; Binding, Competitive; Evoked Potentials; Glioma; Hybrid Cells; Imidazoles; Indo | 1992 |